These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19829670)

  • 1. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
    Li LJ; Chen H; Ren JY; Wang L; Luo Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
    Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
    Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.
    Noguchi Y; Tatsuno I; Suyama K; Shibata T; Yoshida T; Otsuka Y; Fuse M; Takeo C; Saito Y
    J Atheroscler Thromb; 2004; 11(6):335-40. PubMed ID: 15644587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
    Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
    J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
    Kiortsis DN; Elisaf MS
    Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
    Elisaf M; Tsimichodimos V; Bairaktari E; Siamopoulos KC
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):60-3. PubMed ID: 10413068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
    Najib J
    Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Other antihyperuricemic agents].
    Ogino K; Igawa O; Hisatome I
    Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR; Callaghan DJ; Theiss U
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
    Rozza F; Trimarco V; Izzo R; Grassi D; Ferri C
    High Blood Press Cardiovasc Prev; 2016 Dec; 23(4):381-386. PubMed ID: 27644242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
    Takahashi S; Moriwaki Y; Yamamoto T; Tsutsumi Z; Ka T; Fukuchi M
    Ann Rheum Dis; 2003 Jun; 62(6):572-5. PubMed ID: 12759298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.